Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Forced Dose Titration, Safety and Efficacy Study of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Next Previous
X
Search
Trial Profile

A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Forced Dose Titration, Safety and Efficacy Study of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors New River Pharmaceuticals

    • Most Recent Events

    • 02 Feb 2011 Health Canada approved lisdexamfetamine dimesylate capsules for the treatment of ADHD in adolescents and adults based on data from this trial and trial profile 700036858, according to a Shire media release.
    • 01 Sep 2008 Results have been published in the Journal of Clinical Psychiatry 69: 1364-1373, No. 9, Sep 2008. Primary endpoint comment added.
    • 03 May 2008 Results were presented at the 161st Annual Meeting of the American Psychiatric Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top